Gustave Roussy, Cancer Campus, Grand Paris

This study tests whether injecting a special solution (KRC-01) into rectal tumors before radiation can make the radiation work better. The solution increases oxygen inside the tumor, which helps radiation kill cancer cells. About 24 adults with advanced rectal cancer that hasn't …

This phase 3 trial tests whether adding chemotherapy after surgery can prevent aggressive pancreatic neuroendocrine tumors from coming back. About 300 patients will either receive active surveillance alone or 6 cycles of capecitabine-temozolomide pills plus surveillance. The stud…

This phase 3 trial tests whether adding carboplatin to standard therapy can delay cancer growth in men with aggressive prostate cancer that has spread and has either a BRCA gene mutation or neuroendocrine features. About 330 participants will receive either standard care alone or…

This early-stage study tests whether a single infusion of a patient's own modified immune cells (CAR-T cells) is safe for people with severe autoimmune diseases like lupus, rheumatoid arthritis, or scleroderma that haven't improved with standard treatments. Only 6 adults aged 18-…

This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive eith…

This phase 3 trial tests whether CBD oil can reduce joint pain caused by aromatase inhibitors, a common hormone therapy for early breast cancer. About 130 participants will receive either CBD or a placebo for 12 weeks, then switch treatments. The study measures pain interference …

This study tests a digital tool called TRANSCEND-XR that uses extended reality (like virtual reality) to help adolescents and young adults who have finished treatment for testicular cancer. The tool aims to teach them about long-term side effects, when to see a doctor, and how to…

This study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last mo…